Our Library

Cephalosporin-induced Neurotoxicity

Drugline Volume 492

The product information documents of many cephalosporin products have recently been updated to include warnings of neurotoxicity. Cephalosporins are broad-spectrum beta-lactam antibiotics that are commonly used to treat a range of infections. Neurotoxicity has…

Read more

Pneumoccoccal Vaccines

There are currently four pneumococcal vaccines available in Australia. These vaccines protect against disease caused by Streptococcus pneumoniae. While asymptomatic nasopharyngeal carriage can occur, S. pneumoniae is thought to be responsible for at least…

Read more

Availability of Gliclazide

DrugAlert Volume 918

HPS Pharmacies wish to advise that multiple suppliers are experiencing a supply interruption for gliclazide tablets, as follows. Product ARTG Current Status APX-Gliclazide 80mg 337479 Late March 2024 Nidem 80mg 79023 Early March 2024…

Read more

Availability of Morphine Oral Solution

DrugAlert Volume 917

Further to DrugAlert volume 890, HPS Pharmacies wishes to provide an update on the availability of morphine oral solution. While Ordine® Oral Solution was discontinued by Mundipharma in 2023, Arrotex Pharmaceuticals has now announced…

Read more

Tebentafusp for Uveal Melanoma

Drugline Volume 491

Tebentafusp is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of advanced uveal melanoma. Uveal melanoma is a rare cancer originating from melanocytes in the choroid, iris, or ciliary body of…

Read more

Defect Correction for ADT™ Booster

DrugAlert Volume 916

HPS Pharmacies wish to give notice that Seqirus, in consultation with the Therapeutic Goods Administration (TGA), has issued a product defect correction for ADT™ Booster as follows: ADT™ Booster Diphtheria and Tetanus Vaccine ARTG…

Read more
Load More